Company Overview
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.18.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -42.70% |
| 6 Months: | -10.53% |
| 3 Months: | -3.77% |
| 1 Month: | +2.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.05 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 50.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OKYO OKYO Pharma Limited PHARMA | 1.53 | -6.38 | $80.29M | 0.00% | -68.91% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 13.19M | 15.75M | 7.09M | 8.50M |
| Operating Income | - | -13.19M | -15.75M | -7.09M | -8.50M |
| EBITDA | - | -13.18M | -15.75M | -7.10M | -8.47M |
| Interest Expense | - | 96.69K | 1.05M | 870.28K | 473.94K |
| Pretax Income | - | -13.28M | -16.80M | -7.97M | -8.94M |
| Tax Provision | - | -12.20K | 22.42K | -3.26M | 7.99K |
| Net Income | - | -13.27M | -16.83M | -4.71M | -8.95M |
| Diluted EPS | - | -0.61 | -0.57 | -0.12 | -0.24 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 5.20M | 1.54M | 3.68M | 20.98M |
| Current Assets | - | 5.20M | 1.54M | 3.68M | 20.97M |
| Cash & Equivalents | - | 4.05M | 826.85K | 1.56M | 14.59M |
| Inventory | - | - | - | - | - |
| Receivables | - | 980.08K | 580.94K | 1.89M | 170.67K |
| Total Liabilities | - | 7.26M | 7.42M | 9.23M | 8.64M |
| Current Liabilities | - | 7.26M | 7.42M | 9.23M | 8.64M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | 0 | 2.22M | - | - | - |
| Total Equity | - | -2.05M | -5.88M | -5.55M | 12.34M |
| Shares Outstanding | - | 51.04M | 33.34M | 36.02M | 52.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -7.70M | -9.49M | -1.81M | -5.94M |
| Investing Cash Flow | - | -5.92K | 0 | -1.21K | -6.01M |
| Financing Cash Flow | - | 9.32M | 6.21M | 2.66M | 25.02M |
| Capital Expenditure | -1.67K | -5.92K | - | -1.21K | -6.08K |
| Free Cash Flow | - | -7.70M | -9.49M | -1.81M | -5.94M |
| Net Change in Cash | - | 1.62M | -3.28M | 843.60K | 13.08M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 646.4% | 286.2% | 84.8% | -72.6% |
| ROCE % | - | 642.3% | 267.9% | 127.8% | -68.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Woodline Partners LP | 6.96% | 3.65M | $4.97M |
| 2 | Stonepine Capital Management, LLC | 1.64% | 863.00K | $1.17M |
| 3 | Maven Securities Limited | 1.54% | 809.32K | $1.10M |
| 4 | Balyasny Asset Management LP | 1.11% | 580.60K | $789.61K |
| 5 | Opaleye Management Inc. | 0.71% | 375.20K | $510.28K |
| 6 | UBS Group AG | 0.10% | 55.01K | $74.81K |
| 7 | Xtx Topco Ltd | 0.07% | 37.77K | $51.37K |
| 8 | Choreo, LLC | 0.06% | 33.26K | $45.23K |
| 9 | Quantinno Capital Management, LP | 0.06% | 33.26K | $45.23K |
| 10 | Cerity Partners LLC | 0.02% | 12.81K | $17.42K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OKYO
About 111 people are planned for an eye-pain trial after U.S. regulator feedback validated OKYO's path - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPNlEtRk5zYjFWTXlTaVhUSFprNlpRc3lZNEJ0aWg0QWlPYjhpdFpOVkVVMFR1NlBsZ2t1ZzhVVm5HWGdNcS1YVmZxXzVQaG5Bdlg4YkxEQ2tEQW9TdlVBUHFndzlSb053VkFKOC1JZ214MHYzN29hc0VMSTY4TktWRmFJcDV5Xzk1OW9XND…
What Makes OKYO Pharma (OKYO) a New Buy Stock - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOLVJ0SlJUelVjZTB1UXNoMTNoTG5tWklEUnBNSTFwMlB5b1lxNWtST2FMb2xFTzd1SE1weHJCODJMWkZCQlpFRFVJMWxtMUN3S2YwUW00WGhLV3JCUXFMZmNNMnlfYkpPRmotX1FtZzNEUTBveXo1MEFlSzlHUTdTWWtKRzQ5c1FTVXBaSE…
OKYO Pharma (NASDAQ: OKYO) readies Phase 3 trial of eye-pain drug urcosimod - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNMHZ0aGNEa3Q5dlVzeDcxRDNMYjBkMFZaeXB4eHg5ZFhOazNrYzJQaURWUlFxV0JMeXlWY3VVRFl2RjJ4ZG13NVFscnhpM2haN3hGbjQ2bmREVkl3SnNKbTNXMXgzZlY1akdrVW5VSnMxTHVkaEljNXFQNzRxNThMVTNaaG5GZzJTMlA3aF…
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq | OKYO Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPQkVxRUVRSmpFdmVJbWJxblFGbl9YdUs0NEd4MUpDMXZIdzRqaHcwN3lHLVhlTUF5VnZ1U0NLUDJnVmZPVHROZ0JWV0k3azNidmpvTGNTNGRUNldZaUlUazJfb1YzM3ExNXVSQm5nMmY4b283Ty1lVlFiYm9VUkNfQnBzMnFsS09lbXNDOE…
H.C. Wainwright cuts OKYO Pharma stock price target to $5 on share count - Investing.com
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRzdSUVh6ZXFmUXM3bVNQSC1GOGtTNUVIOFNsTnlMeEpvWkJsSTB1Q2hOT0QwaTVHRm45cUNGN21teHNKRkQzRzg2WFQ2bmFZTUNzNVFVQ01PR1RuRmpMdF8tMFR6WEhEYkthLWU4S0RPWW5kaUN4dU1lNHp5TXNiemNuczFJRlFub3FUTF…
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPRlAxSE5BU3hFUm1sdnJ0SV9rY0FncVVobG43V05QLTQ4b3NrMUlsWUxyYlQtTGxaWFNnZlpBY2g0OF9ZT3E1d3hMUzJLSTFCaC05Q0pBS0JzLWZiVkgxY080enpkY3VxWUxxSnlPaFZoUEdoZVh3d3J2ZGptSWFaLUlLcENHMUkzT21aNH…
OKYO — Frequently Asked Questions
What is the current share price of OKYO Pharma Limited (OKYO)?
As of 2026-09-19 21:16 PDT, OKYO Pharma Limited (OKYO) trades at $1.53 on NasdaqCM. Its 52-week range is $1.37 to $3.11.
What is the market capitalisation of OKYO?
OKYO Pharma Limited (OKYO) has a market capitalisation of $80.29M on NasdaqCM.
What is the P/E ratio of OKYO?
OKYO trades at a trailing price-to-earnings (P/E) ratio of -6.38. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.79.
Is OKYO a good stock to buy?
This page provides a data-driven analysis of OKYO Pharma Limited (OKYO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.